907. Deputy Mark Ward asked the Minister for Health in light of a report (details supplied), the safety protocols in place in Irish hospitals in relation to nitrous oxide use; and if staff are made aware of potential side effects due to exposure. [73701/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Mark Ward .
109 questions match, newest first.
149. Deputy Mark Ward asked the Minister for Health the supports available through the HSE to assist with the cost of a private dyslexia assessment for children who are not meeting developmental milestones and face long delays in the public system. [72984/26]
173. Deputy Mark Ward asked the Minister for Health the number of people who have presented at accident and emergency departments since 2021 for suspected spiking; the current care pathways for victims within the healthcare system; and the testing currently available; and if this will be updated. [72985/26]
609. Deputy Mark Ward asked the Minister for Health if the MCAP review has commenced; if stakeholders have been appointed to the review group; and the length of time the review is expected to take once it begins. [70162/26]
655. Deputy Mark Ward asked the Minister for Health for an update on the school immunisation programme; the number of vacancies in the Dublin area for the school immunisation team; to comment on the cancellation of junior infant vaccines MMR and Tdap boosters scheduled for the school (details supplied); and the steps that are being taken to address this. [70215/26]
1264. Deputy Mark Ward asked the Minister for Health for an update on staffing numbers in the primary care centre in Cherry Orchard; the number of vacancies per post; the waiting times for child psychology, child occupational therapy and child physiotherapy; and the number of children waiting for each of these services, by month, in tabular form. [64589/26]
1471. Deputy Mark Ward asked the Minister for Health the HSE supports that are available to people with Addisons disease; and if additional supports will be considered in the future. [65917/26]
707. Deputy Mark Ward asked the Minister for Health the steps she will take in relation to nitrous oxide following the publication of the Oireachtas Joint Committee on Drug Use Final Report; her views on the report’s recommendations relating to nitrous oxide; and if she will make a statement on the matter. [50816/26]
548. Deputy Mark Ward asked the Minister for Health if belzutifan will be made available to people with Von Hippel-Lindau disease; the steps being taken to make this therapy available; and if she will make a statement on the matter. [50755/26]
896. Deputy Mark Ward asked the Minister for Health the annual budget for the HSE pest control service in Dublin; the number of staff for Dublin for each year since 2016, in tabular form; and if she will make a statement on the matter. [49533/26]
685. Deputy Mark Ward asked the Minister for Health if funding for community prison links workers will be transferred from the Department of Justice, Home Affairs and Migration to the HSE; if so, the timeline for this.; and if she will make a statement on the matter. [47007/26]
884. Deputy Mark Ward asked the Minister for Health if givinostat will be made available for children with Duchenne muscular dystrophy; to provide an update on steps taken by the HSE since a commercial proposal was received from a company (details supplied); when this therapy will be made available to the public; and if she will make a statement on the matter. [45156/26]
949. Deputy Mark Ward asked the Minister for Health the reason the State is not pursuing fair pricing on an EU-wide basis regarding the topic of givinostat therapy for Duchenne muscular dystrophy; the reason this is only being considered in the context of the Irish market; if precedence for EU-wide negotiation has been used for drug pricing; and if she will make a statement on the matter. [45404/26]
2144. Deputy Mark Ward asked the Minister for Health the funding opportunities for organisations (details supplied) that provide meditation and mindfulness practices which promote inner peace, reduce stress, and improve mental health; to outline the way they can apply for these supports; and if she will make a statement on the matter. [42961/26]
323. Deputy Mark Ward asked the Minister for Health if she will consider running a pilot orphan drug early-access programme in order that children with Duchenne muscular dystrophy can access givinostat; if a pricing and reimbursement application is being progressed by the HSE for givinostat; and if she will make a statement on the matter. [38448/26]
324. Deputy Mark Ward asked the Minister for Health if givinostat will be made available for children with Duchenne muscular dystrophy; and if she will make a statement on the matter. [38449/26]
1223. Deputy Mark Ward asked the Minister for Health the progress to date on Action 10 of the HSE Position Paper (details supplied); the specific measures undertaken to date; the current status of implementation; the timelines for any outstanding elements due to be completed within five years of publication; and if she will make a statement on the matter. [37679/26]
209. Deputy Mark Ward asked the Minister for Health if she will advise on the CORU registration adaptation requirements for individuals who have moved to the State (details supplied); and if she will make a statement on the matter. [28798/26]
436. Deputy Mark Ward asked the Minister for Health will consider running a pilot orphan drug early-access programme in order that children with Duchenne muscular dystrophy can access givinostat; if a pricing and reimbursement application has been received by the HSE for givinostat; and if she will make a statement on the matter. [23049/26]
437. Deputy Mark Ward asked the Minister for Health if givinostat will be made available for children with Duchenne muscular dystrophy; and if she will make a statement on the matter. [23050/26]
977. Deputy Mark Ward asked the Minister for Health if she is aware of the barriers currently faced by patients in Ireland living with lipoedema, including the absence of a published national HSE care pathway, limited access to conservative management such as compression therapy and manual lymphatic drainage, and delays or difficulties accessing treatment through the cross-Border healthcare directive; the steps her D…
978. Deputy Mark Ward asked the Minister for Health whether the HSE working group established in 2023 to develop a national care pathway for lipoedema has completed its work; when the pathway is expected to be published; and whether patient advocacy organisations, including an organisation (details supplied) will be included in the development and implementation of this pathway. [22198/26]
979. Deputy Mark Ward asked the Minister for Health if her Department intends to review the operation of private health insurers in relation to coverage for medically indicated liposuction procedures for lipoedema patients, in light of concerns regarding inconsistent decision-making, the use of criteria designed for lymphoedema rather than lipoedema, and practices that may result in patients being forced to rely on t…
1668. Deputy Mark Ward asked the Minister for Health the specific measures which he will put in place to protect the independent, community-led role of Local Drug and Alcohol Task Forces under the proposed regional governance arrangements in the draft National Drugs Strategy 2026-2029; and if she will make a statement on the matter. [18290/26]
1778. Deputy Mark Ward asked the Minister for Health the existing public support pathways for adults with ADHD; the supports available to families who cannot afford private care; and if she will make a statement on the matter. [18922/26]